# Phase 2 Leukemia, Myelogenous: 25 recruiting (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials in phase 2 for Leukemia, Myelogenous, Chronic, BCR-ABL Positive that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/leukemia-myelogenous-chronic-bcr-abl-positive

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 14, 2026 | NCT07819396 | Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute... | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819396) |
| September 4, 2026 | NCT07804901 | Asciminib Frontline Risk Adapted | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Chronic Myeloid Leukemia (CML) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804901) |
| August 27, 2026 | NCT07789574 | Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Myeloid Leukemia (CML) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789574) |
| April 20, 2026 | NCT07538401 | ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in... | University Health Network, Toronto | Phase 2 | Not yet recruiting | Chronic Myeloid Leukemia (CML) in | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538401) |
| January 21, 2026 | NCT07354074 | Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP | Novartis Pharmaceuticals | Phase 2 | Recruiting | Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07354074) |
| December 8, 2025 | NCT07269470 | Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Chronic Myeloid Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07269470) |
| March 5, 2025 | NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With... | Center for International Blood and Marrow Transplant Research | Phase 2 | Recruiting | AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic... | 358 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06859424) |
| February 10, 2025 | NCT06817720 | Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Chronic Myeloid Leukemia | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06817720) |
| August 1, 2024 | NCT06532084 | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen | St. Petersburg State Pavlov Medical University | Phase 2 | Recruiting | Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Myeloproliferative Neoplasm | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06532084) |
| July 23, 2024 | NCT06514534 | Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. | Novartis Pharmaceuticals | Phase 2 | Recruiting | Chronic Myeloid Leukemia (CML) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06514534) |
| June 12, 2024 | NCT06453902 | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | Shenzhen TargetRx Co., Ltd. | Phase 2 | Recruiting | Chronic Myeloid Leukemia, Accelerated Phase CML | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06453902) |
| May 10, 2024 | NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML | Gruppo Italiano Malattie EMatologiche dell'Adulto | Phase 2 | Recruiting | CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase, Chronic Myeloid Leukemia, BCR/ABL-Positive, Chronic... | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06409936) |
| April 9, 2024 | NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial | Imperial College London | Phase 2 | Recruiting | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06355583) |
| February 1, 2024 | NCT06236724 | Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Chronic Myeloid Leukemia | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06236724) |
| September 28, 2023 | NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing... | City of Hope Medical Center | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1... | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06059391) |
| August 28, 2023 | NCT06013423 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid... | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06013423) |
| April 10, 2023 | NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia... | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05805605) |
| April 5, 2023 | NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | University of Florida | Phase 2 | Recruiting | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05800210) |
| May 17, 2021 | NCT04888741 | Methods of T Cell Depletion Trial (MoTD) | University of Birmingham | Phase 2 | Recruiting | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Non... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04888741) |
| April 8, 2021 | NCT04838041 | Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML)... | Medical College of Wisconsin | Phase 2 | Recruiting | Chronic Phase Chronic Myelogenous Leukemia | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04838041) |
| December 12, 2019 | NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adult Diffuse Large Cell Lymphoma, Anaplastic... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04195633) |
| October 19, 2017 | NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03314974) |
| September 5, 2016 | NCT02889003 | Second STOP After Pioglitazone Priming in CML Patients | Versailles Hospital | Phase 2 | Recruiting | Chronic Myeloid Leukemia (CML) | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02889003) |
| April 16, 2014 | NCT02115295 | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive... | 508 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02115295) |
| December 11, 2012 | NCT01746836 | Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01746836) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| M.D. Anderson Cancer Center | 5 |
| Fred Hutchinson Cancer Center | 3 |
| Masonic Cancer Center, University of Minnesota | 2 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 2 |
| Versailles Hospital | 1 |
| University Health Network, Toronto | 1 |
| University of Birmingham | 1 |
| Center for International Blood and Marrow Transplant Research | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| Shenzhen TargetRx Co., Ltd. | 1 |
| Imperial College London | 1 |
| City of Hope Medical Center | 1 |
| Medical College of Wisconsin | 1 |
| St. Petersburg State Pavlov Medical University | 1 |
| University of Florida | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| Germany | 3 |
| France | 3 |
| United Kingdom | 2 |
| China | 2 |
| Spain | 2 |
| Australia | 1 |
| Brazil | 1 |
| Canada | 1 |
| Hungary | 1 |
| Italy | 1 |
| Japan | 1 |
| Netherlands | 1 |
| Poland | 1 |
| Singapore | 1 |
| South Korea | 1 |
| Thailand | 1 |
| Vietnam | 1 |
| Russia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Vocational and technical schools in the United States](https://specstream.ai/data/businesses/vocational-and-technical-schools/united-states)
- [Bangladeshi restaurants in the United States](https://specstream.ai/data/businesses/bangladeshi-restaurants/united-states)
- [Cuban restaurants in the United States](https://specstream.ai/data/businesses/cuban-restaurants/united-states)
- [Gastroenterology practices in the United States](https://specstream.ai/data/businesses/gastroenterology-practices/united-states)
- [Lighting fixtures and equipment companies in the United States](https://specstream.ai/data/businesses/lighting-fixtures-and-equipment-companies/united-states)
- [Plastic and reconstructive surgery practices in the United States](https://specstream.ai/data/businesses/plastic-and-reconstructive-surgery-practices/united-states)
